Highlights from the 23 May 2002 supplement: Safety and Toxicity of Individual Antiretroviral Agents in Pregnancy
The supplement Safety and Toxicity of Individual Antiretroviral Agents in Pregnancy has been updated to include changes to the information for two drugs:
- Tenofovir disoproxil fumerate (Viread). New information on teratogenicity/developmental toxicity animal studies and placental and breast milk passage in humans appears on page 3.
- Efavirenz (Sustiva). New information regarding teratogenicity/developmental toxicity animal studies and human studies in pregnancy begins on page 7.
These changes are highlighted in the text.
This document is a supplement to both the Guidelines for the Use of Antiretroviral Agents in HIV-Infected Adults and Adolescents (4 February 2002) and the Public Health Service Task Force Recommendations for Use of Antiretroviral Drugs in Pregnant HIV-1-Infected Women for Maternal Health and Interventions to Reduce Perinatal HIV-1 Transmission in the United States (4 February 2002). Please note that the content of these two guidelines has not changed since 4 February 2002.
A new feature has been added to the online version of the perinatal guidelines. Hyperlinks from the references to online published literature are now available. We expect to offer the same feature for the other guidelines in the near future.
The Guidelines and all supplements are available for downloading from